ReviewJournal of ophthalmology2015
Graves' Ophthalmopathy: VISA versus EUGOGO Classification, Assessment, and Management.
Review in Journal of ophthalmology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 105 papers, 6 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
105 citing papers in PubMed, 6 syntheses or guidelines pooled it, 227 citations in OpenAlex.
- Multi-Omics Approaches to Discover Biomarkers of Thyroid Eye Disease: A Systematic Review.International journal of biological sciences · 2024Pooled it
- TSH receptor autoantibody levels post-total thyroidectomy in Graves' ophthalmopathy: a meta-analysis.Langenbeck's archives of surgery · 2023Pooled it
- Magnetic resonance imaging parameters on lacrimal gland in thyroid eye disease: a systematic review and meta-analysis.BMC ophthalmology · 2023Pooled it
- A systematic review of multimodal clinical biomarkers in the management of thyroid eye disease.Reviews in endocrine & metabolic disorders · 2022Pooled it
- Network Meta-Analysis of Different Intravenous Glucocorticoid Regimes for the Treatment of Graves' Orbitopathy.Frontiers in pharmacology · 2022Pooled it
- Tocilizumab for thyroid eye disease.The Cochrane database of systematic reviews · 2018Pooled it
- A Consensus-Based Clinical Activity Score Atlas for Thyroid Eye Disease in East Asian Patients: The Korean Society of Ophthalmic Plastic and Reconstructive Surgery Initiative.Korean journal of ophthalmology : KJO · 2026Article
- Pupillometric alterations in Graves' disease: Beyond thyroid functional status.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2026Article
- A Deep Learning Framework for Predicting Teprotumumab Treatment Response in Thyroid Eye Disease.Ophthalmology science · 2026Article
- Quantitative Chemical Exchange Saturation Transfer MRI for Diagnosing Thyroid-Associated Ophthalmopathy Activity: A Prospective Feasibility Study.Korean journal of radiology · 2026Article
- Interpretable machine learning for severity classification of thyroid eye disease using orbital anatomical features.Frontiers in medicine · 2026Article
- How to manage thyroid eye disease: recent advances - a narrative review.Drugs in context · 2026Review
- Case Report: Marked bilateral optic disc edema as the presenting manifestation of thyroid eye disease with dysthyroid optic neuropathy.Frontiers in ophthalmology · 2026Article
- Dipeptidyl peptidase-4 inhibitors suppress myofibroblastic differentiation and hyaluronan synthesis in Graves' orbitopathy fibroblasts.Frontiers in endocrinology · 2026Article
- Orbital decompression with intraorbital corticosteroid injection during the active phase of thyroid eye disease: outcomes in a real-world cohort.Frontiers in ophthalmology · 2026Article
- Incidence and risk factors of tocilizumab-induced hypofibrinogenemia in patients with thyroid eye disease: a single-center retrospective study.Frontiers in endocrinology · 2026Article
- Targeting IL-6 Receptor Signaling with Satralizumab in Thyroid Eye Disease: Design of the Phase 3 SatraGO-1 and SatraGO-2 Trials.Ophthalmology and therapy · 2025Article
- Rapid multiparametric quantitative MRI for predicting the activity of thyroid-associated ophthalmopathy: combination with clinical characteristics.European radiology · 2025Article
- Initial strabismus surgery in patients with thyroid eye disease: outcomes and dose-response in various types of procedure.International ophthalmology · 2025Article
- The efficacy of radiotherapy for steroid-resistant thyroid eye disease: clinical outcomes in orbital inflammation and exophthalmos.Radiation oncology journal · 2025Article
45 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Graves' ophthalmopathy (GO) is an autoimmune inflammatory disorder associated with thyroid disease which affects ocular and orbital tissues. GO follows a biphasic course in which an initial active phase of progression is followed by a subsequent partial regression and a static inactive phase. Although the majority of GO patients have a mild, self-limiting, and nonprogressive ocular involvement, about 3-7% of GO patients exhibit a severe sight-threatening form of the disease due to corneal exposure or compressive optic neuropathy. An appropriate assessment of both severity and activity of the disease warrants an adequate treatment. The VISA (vision, inflammation, strabismus, and appearance), and the European Group of Graves' Orbitopathy (EUGOGO) classifications are the two widely used grading systems conceived to assess the activity and severity of GO and guide the therapeutic decision making. A critical analysis of classification, assessment, and management systems is reported. A simplified "GO activity assessment checklist" for routine clinical practice is proposed. Current treatments are reviewed and management guidelines according to the severity and activity of the disease are provided. New treatment modalities such as specific monoclonal antibodies, TSH-R antagonists, and other immunomodulatory agents show a promising outcome for GO patients.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.